Teneligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies.

Abstract

This article provides commentary on the article by Zhang et al. In this original research, Zhang et al investigated the therapeutic potential of teneligliptin for diabetic cardiomyopathy (DCM), which was mediated by targeting the NOD-like receptor protein 3 (NLRP3) inflammasome. Through the use of both in vivo and in vitro models, the study demonstrated that teneligliptin alleviates cardiac hypertrophy, reduces myocardial injury, and mitigates the inflammatory responses associated with DCM. These findings suggest that teneligliptin's cardioprotective effects are mediated through the inhibition of NLRP3 inflammasome activation, positioning it as a promising therapeutic option for managing DCM in diabetic patients.